By Cocer Peptides 
kwanaki 13 da suka gabata
DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.
Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da duk wani yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.
Bayanin Semaglutid
Semaglutid labari ne mai glucagon-kamar peptide-1 agonist mai karɓa (GLP-1 RA). Glucagon-kamar peptide-1 (GLP-1) wani hormone ne da jikin ɗan adam ke ɓoye ta halitta wanda ke taka muhimmiyar rawa wajen daidaita glucose na jini. Lokacin da matakan glucose na jini ya tashi, GLP-1 yana ɓoye kuma yana daidaita matakan glucose na jini ta hanyoyi daban-daban. Koyaya, a cikin marasa lafiya na masu ciwon sukari, yawan ɓoyewar GLP-1 baya isa ko tasirin sa bai isa ba. Semaglutid yana ɗaure ga masu karɓar GLP-1, yana kwaikwayon tasirin ilimin lissafin jiki na GLP-1, don haka yana yin tasirin warkewa don ciwon sukari da sarrafa nauyi.
Hoto 1 Jiyya don kiba da tasirin su akan asarar nauyi
Matsayin Semaglutid a cikin Jiyya na Ciwon sukari
Inganta Sigar Insulin
A ƙarƙashin yanayin ilimin lissafi, lokacin da matakan glucose na jini ya tashi, ƙwayoyin enteroendocrine a cikin hanji suna ɓoye GLP-1. GLP-1 yana ɗaure ga masu karɓar GLP-1 akan saman sel beta na pancreatic, yana kunna jerin hanyoyin sigina don haɓaka haɓakar insulin. Semaglutid kuma yana iya ɗaure musamman ga masu karɓar GLP-1 akan saman sel beta na pancreatic, yana haɓaka haɓakar insulin ta hanyar dogaro da glucose. Wannan yana nufin cewa lokacin da matakan glucose na jini ya tashi, Semaglutid ya inganta ingantaccen sakin insulin don rage matakan glucose na jini; Lokacin da matakan glucose na jini ya kasance cikin kewayon al'ada, tasirin sa akan haɓaka haɓakar insulin yana da rauni, don haka yana rage haɗarin hypoglycemia. Nazarin ya nuna cewa bayan jiyya tare da Semaglutid, matakan insulin na marasa lafiya sun inganta sosai, kuma ana iya sarrafa matakan glucose na jini yadda ya kamata.
Hoto na 2: Hanya ta sama mai nauyi-tsakiya tare da ƙarin ƙasa, glucose-centric, da hanyoyin cardiometabolic. Magunguna na tushen Incretin sun riga sun fara aiki a mafi girman mataki.
Ba kamar asirin insulin na al'ada ba, kamar sulfonylureas, wanda ke ci gaba da haɓaka haɓakar insulin ba tare da la'akari da matakan glucose na jini ba kuma yana iya haɓaka haɗarin hypoglycemia, Semaglutid's glucose-concentration-dependent insulin secretion Properties yana ba shi damar rage matakan glucose na jini yadda ya kamata yayin da yake rage abin da ya faru na hypoglycemia, yana ba da mafi aminci da ingantaccen zaɓi na sarrafa glucose na jini ga masu ciwon sukari.
Hana fitar da glucagon
Glucagon hormone ne da ke ɓoye ta ƙwayoyin α pancreatic wanda ke haɓaka matakan glucose na jini, yana aiki sabanin insulin. A cikin masu ciwon sukari, ƙwayar glucagon sau da yawa yakan kasance ba tare da hanawa ba ko da lokacin hawan glucose na jini. Semaglutid yana aiki akan masu karɓa na GLP-1 akan ƙwayoyin α pancreatic don hana ɓoyewar glucagon. Lokacin da ƙwayar glucagon ta ragu, ana hana glycogenolysis na hanta da matakan gluconeogenesis, yana rage samar da glucose na endogenous kuma yana ƙara rage matakan glucose na jini. Masana kimiyya sun tabbatar da cewa a cikin nau'in masu ciwon sukari na 2 da aka bi da su tare da Semaglutid, matakan glucagon na plasma suna raguwa sosai, yadda ya kamata rage tasirin glucose na hanta da kuma taka muhimmiyar rawa wajen daidaita matakan glucose na jini.
Jinkirta zubar ciki
Semaglutid yana aiki akan masu karɓa na GLP-1 a cikin sashin gastrointestinal don jinkirin zubar da ciki. Zubar da ciki da sauri yana sa abinci ya shiga cikin ƙananan hanji cikin sauri, yana haifar da haɓakar matakan glucose na jini cikin sauri. Ta hanyar jinkirta zubar da ciki, abinci ya daɗe a cikin ciki kuma yana shiga cikin ƙananan hanji da sannu a hankali, yana haifar da ɗaukar glucose a hankali a hankali tare da hana haɓakar hauhawar matakan glucose na jini. Wannan tasirin yana taimakawa wajen kiyaye matakan glucose na jini da kwanciyar hankali da kuma rage jujjuyawar glucose na jini. A cikin wasu gwaje-gwaje na asibiti, marasa lafiya da aka yi wa magani tare da Semaglutid sun sami raguwa mai yawa a cikin kololuwar glucose na jini na postprandial da ƙananan sauye-sauyen glucose na jini, haɓaka ingancin sarrafa glucose na jini gaba ɗaya. Bugu da ƙari, jinkirin zubar da ciki na iya haifar da jin daɗin cikawa, yana taimakawa wajen rage cin abinci kuma ta haka yana taimakawa wajen sarrafa glucose na jini da sarrafa nauyi daga wani kusurwa.
Hoto 3: Hanyar Semaglutid don Gudanar da Kiba
Inganta aikin β-Cell
Hyperglycemia na yau da kullun na iya lalata ƙwayoyin β na pancreatic, yana haifar da raguwar aiki a hankali. Semaglutid ba wai kawai rage sukarin jini bane ta hanyar haɓaka haɓakar insulin amma kuma yana ba da kariya da gyara ƙwayoyin β na pancreatic, ta haka yana haɓaka aikin β cell. Nazarin kimiyya ya nuna cewa semaglutide na iya kunna wasu hanyoyin siginar siginar intracellular don haɓaka haɓakar β-cell, hana β-cell apoptosis, don haka ƙara lamba da aiki na β-cell. A cikin gwaje-gwajen dabba da wasu nazarin asibiti, an lura cewa bayan yin amfani da Semaglutid, an haɓaka ƙarfin siginar insulin na ƙwayoyin β, kuma an inganta juriya na insulin. Wannan yana da matukar mahimmanci ga maganin ciwon sukari na 2 na dogon lokaci, saboda yana taimakawa rage ci gaban cutar da rage haɗarin rikice-rikice na ciwon sukari.
Aikace-aikace na Semaglutid a cikin Jiyya na Ciwon sukari
Semaglutid yana da hanyoyin aikace-aikace daban-daban a cikin maganin ciwon sukari. Ga sabbin cututtukan da aka gano masu ciwon sukari na 2, idan matakan glucose na jini ba su da girma sosai kuma babu wasu takamaiman rikice-rikice ko wasu cututtuka masu tsanani, ana iya ɗaukar monotherapy tare da Semaglutid. Nazarin asibiti ya nuna cewa wasu sababbin marasa lafiya da aka gano sun sami raguwa sosai a matakan haemoglobin A1c (HbA1c) da asarar nauyi bayan wani lokaci na monotherapy. Alal misali, a cikin jerin nazarin PIONEER, marasa lafiya da aka bi da su tare da Semaglutid monotherapy na baka sun sami raguwa mai yawa a cikin matakan HbA1c idan aka kwatanta da ƙungiyar placebo, tare da kyakkyawan aminci da haƙuri. Amfanin monotherapy shi ne cewa yana guje wa haɗarin hulɗar miyagun ƙwayoyi da ke hade da haɗin gwiwa, kuma gudanarwa mai sauƙi yana taimakawa wajen inganta haƙuri ga jiyya.
Ana iya amfani da Semaglutid a hade tare da wasu magunguna. Lokacin da aka haɗe shi da metformin, wanda shine magani na farko don nau'in ciwon sukari na 2, yana inganta juriya na insulin kuma yana rage fitowar glucose na hanta. Magungunan biyu suna da ingantattun hanyoyin aiki, suna ba da damar sarrafa glucose na jini mafi inganci. Nazarin ya nuna cewa wannan tsarin haɗin gwiwar yana ƙara rage matakan HbA1c kuma yana haifar da asarar nauyi. Alal misali, a wasu gwaje-gwaje na asibiti, marasa lafiya da aka bi da su tare da metformin wanda ya kara Semaglutid sun sami raguwa mafi girma a cikin matakan HbA1c idan aka kwatanta da waɗanda suka ci gaba da metformin monotherapy, tare da ƙarin asarar nauyi, ba tare da karuwa mai yawa a cikin hadarin hypoglycemia ba. Wannan tsarin ya dace da marasa lafiya waɗanda matakan glucose na jini ba su da isasshen sarrafawa tare da metformin monotherapy.
Ga marasa lafiya da nau'in ciwon sukari na 2 waɗanda ke da matakan glucose na jini kuma suna buƙatar maganin insulin, ƙara Semaglutid zuwa maganin insulin na iya rage adadin insulin. A cikin maganin insulin, marasa lafiya sukan fuskanci al'amura kamar haɓaka nauyi da haɓaka haɗarin hypoglycemia. Lokacin amfani da shi a hade, sakamakon Semaglutid na inganta haɓakar insulin da hana ƙwayar glucagon zai iya inganta amfani da insulin, rage sashi, kuma ta haka ne ya rage haɗarin samun nauyi da hypoglycemia. Misali, a cikin wasu nazarin asibiti, marasa lafiya waɗanda suka ƙara Semaglutid zuwa maganin insulin sun sami raguwar matsakaicin adadin insulin, tare da ƙarin raguwa a cikin matakan HbA1c, asarar nauyi, da raguwa a cikin mitar abubuwan hypoglycemia.
Hakanan ana iya amfani da Semaglutid a hade tare da sauran magungunan antidiabetic kamar masu hana SGLT2. Masu hana SGLT2 suna rage yawan glucose na jini ta hanyar haɓaka haɓakar glucose a cikin fitsari. Haɗin waɗannan biyun na iya ƙara haɓaka sarrafa glucose na jini ta hanyoyi daban-daban kuma yana iya samun tasirin daidaitawa a cikin sarrafa nauyi.
Matsayin Semaglutid a cikin sarrafa nauyi
Ciwon kai
Semaglutid yana aiki akan masu karɓar GLP-1 a cikin tsarin juyayi na tsakiya, musamman a cikin hypothalamus. Hypothalamus shine yanki mai mahimmanci a cikin jiki don daidaita yanayin ci da kuzari. Bayan ɗaure ga masu karɓar GLP-1 a cikin hypothalamus, semaglutide na iya daidaita sakin neuropeptides, kamar rage ɓoyewar neuropeptide Y (NPY), wanda shine babban abin motsa sha'awa. Bugu da ƙari, Semaglutid na iya ƙara yawan ayyukan proopiomelanocortin (POMC) neurons, wanda kunnawa ya haifar da alamun satiety. Ta hanyar waɗannan hanyoyin, Semaglutid yana hana ci abinci yadda ya kamata, yana jagorantar marasa lafiya don rage cin abinci. A cikin gwaje-gwaje na asibiti, marasa lafiya masu kiba ko masu kiba masu amfani da Semaglutid sun ba da rahoton rage cin abinci da rage cin abinci, yana kafa tushe don asarar nauyi.
Ƙara yawan kuɗin makamashi
Baya ga hana ci abinci, Semaglutid kuma na iya yin tasiri ga metabolism na makamashi, yana ƙara kashe kuzari. Bincike ya nuna cewa Semaglutid na iya ƙara yawan kashe kuzari ta hanyar daidaita ayyukan ƙwayar adipose mai launin ruwan kasa. Brown adipose tissue wani nau'in kitse ne na musamman wanda aikinsa na farko shine cinye makamashi ta hanyar thermogenesis. Semaglutid na iya kunna wasu hanyoyin sigina a cikin ƙwayar adipose mai launin ruwan kasa, inganta iskar oxygen da fatty acid da thermogenesis. Bugu da ƙari, Semaglutid na iya rinjayar metabolism na makamashi a cikin kyallen takarda kamar tsoka, ƙara yawan kashe kuzari ko da a hutawa. Misali, a gwaje-gwajen dabbobi, bayan gudanar da Semaglutid, yawan kuzarin makamashin dabbobi ya karu, kuma nauyin jikinsu ya ragu ko da lokacin cin abinci ya kasance iri daya, wanda ke nuna cewa Semaglutid yana taka rawa mai kyau wajen sarrafa nauyi ta hanyar kara kashe kuzari.
Regulation na mai metabolism
Semaglutid kuma yana da tasiri mai tasiri akan metabolism na mai. Yana iya inganta rushewar kitse, rage yawan kitse, da hana ajiyar mai. A cikin hanta, Semaglutid na iya hana ayyukan enzymes irin su fatty acid synthase, don haka rage ƙwayar acid mai kitse. Bugu da ƙari, a cikin ƙwayar adipose, Semaglutid na iya inganta raguwar kitse, ƙara sakin fatty acids kyauta, da sauƙaƙe shigar su cikin mitochondria don rushewar oxidative, ta haka ne rage yawan ajiyar mai. Nazarin asibiti ya nuna cewa bayan wani lokaci na jiyya tare da Semaglutid, abubuwan da ke cikin jikin marasa lafiya, musamman abubuwan kitse na visceral, sun ragu. Wannan ba wai kawai yana taimakawa wajen asarar nauyi ba har ma yana da tasiri mai mahimmanci don inganta ciwo na rayuwa da rage haɗarin cututtukan zuciya.
Aikace-aikacen Semaglutid a cikin Gudanar da Weight
Ga marasa lafiya masu kiba ko kiba tare da cututtuka masu alaƙa
Semaglutid yana da ƙayyadaddun adadin yawan jama'a don sarrafa nauyi. Ga marasa lafiya masu kiba tare da BMI ≥30 kg/m² ko marasa lafiya masu kiba tare da BMI ≥27 kg/m² kuma aƙalla yanayin da ke da alaƙa da nauyi (kamar hauhawar jini, nau'in ciwon sukari na 2, ko hypercholesterolemia), magani ne mai inganci mai sarrafa nauyi. Jerin STEP na gwaje-gwaje na asibiti ya nuna babban hasara mai nauyi a cikin marasa lafiya da aka bi da su. A cikin binciken MATAKI na 1, marasa lafiya da aka bi da su sun sami matsakaicin asarar nauyi na kusan 15% sama da makonni 68, yayin da rukunin placebo ya rasa kusan 2.4%. Wadannan sakamakon sun nuna cewa zai iya taimakawa marasa lafiya masu kiba ko kiba tare da yanayin da ke da alaƙa da su cimma mahimmanci da ci gaba da asarar nauyi, inganta sakamakon kiwon lafiya, da kuma rage haɗarin cututtuka masu alaka da kiba.
Haɗe tare da shiga tsakani na rayuwa
A cikin sarrafa nauyi, ana amfani da Semaglutid yawanci a hade tare da ayyukan rayuwa, gami da rage yawan adadin kuzari da haɓaka aikin jiki. Idan asarar nauyi ya dogara ne akan magani kawai ba tare da canza yanayin salon rayuwa mara kyau ba, sau da yawa tasirin ba zai dorewa ba. Haɗuwa da hanyoyi guda biyu yana da tasiri mai tasiri: magani yana hana ci abinci kuma yana ƙara yawan kuzarin makamashi, yayin da kula da abinci ya rage yawan adadin kuzari da kuma ƙara yawan aikin jiki yana kara yawan kuzarin makamashi, wanda zai haifar da asarar nauyi mai mahimmanci da ci gaba. Alal misali, a wasu ayyukan asibiti, marasa lafiya waɗanda ke bin tsarin rage cin abinci mai ƙarancin kalori wanda masanin abinci ya ɓullo da su kuma suna ƙara lokacin motsa jiki na mako-mako yayin da suke karɓar magani suna samun sakamako mafi kyau na asarar nauyi fiye da waɗanda suka dogara kawai ga magani ko tsarin rayuwa. Wannan haɗin gwiwar haɗin gwiwar yana jaddada mahimmancin gudanarwa mai mahimmanci a cikin kula da nauyi, taimakawa marasa lafiya su kafa salon rayuwa mai kyau da kuma cimma nasarar sarrafa nauyi na dogon lokaci.
Kammalawa
Semaglutid yana nuna mahimmancin yuwuwar a cikin jiyya na ciwon sukari da sarrafa nauyi. A cikin jiyya na ciwon sukari, yana sarrafa glucose na jini yadda ya kamata ta hanyoyi da yawa, yana inganta aikin β-cell, kuma ana iya amfani dashi azaman monotherapy ko a hade tare da sauran magungunan antidiabetic. A cikin sarrafa nauyi, yana hana ci, yana ƙara kashe kuzari, kuma yana daidaita metabolism na mai, yana sa ya dace da marasa lafiya masu kiba ko masu kiba masu alaƙa. Lokacin da aka haɗa shi da tsarin rayuwa, yana haifar da sakamako mafi kyau.
Sources
[1] Salvador R, Moutinho CG, Sousa C, et al. Semaglutid a matsayin GLP-1 Agonist: Ci gaba a cikin Jiyya na Kiba [J]. Magunguna, 2025,18 (3).DOI:10.3390/ph18030399.
[2] Memon A, Tehrim M, Kumari B. Semaglutid: sabon alfijir ga masu ciwon sukari[J]. Jaridar Ƙungiyar Likitocin Pakistan, 2023,73 (3): 721.DOI: 10.47391 / JPMA.7558.
[3] Colin IM, Gérard K M. Sau ɗaya-mako 2.4 MG Semaglutid for Weight Management in Obesity: A Game Changer?[J]. Touchrev Endocrinol, 2022,18 (1): 35-42.DOI: 10.17925/EE.2022.18.1.35.
[4] Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): sabon maganin rage nauyi don sarrafa nauyi na yau da kullun[J]. Jaridar Magungunan Bincike, 2022,70 (1): 5-13.DOI: 10.1136/jim-2021-001952.
[5] Mares AC, Chatterjee S, Mukherjee D. Semaglutid don asarar nauyi da rage haɗarin cardiometabolic a cikin kiba / kiba [J]. Ra'ayi na Yanzu a Ilimin Zuciya, 2022,37(4):350-355.DOI:10.1097/HCO.0000000000000955.
[6] Chudleigh RA, Bain S C. Semaglutid allura don kula da manya da nau'in ciwon sukari na 2 [J]. Binciken Kwararru na Magungunan Magunguna na Clinical, 2020,13(7):675-684.DOI:10.1080/17512433.2020.1776108.
[7] Gomez-Peralta F, Abreu C. Bayanan martaba na semaglutide a cikin sarrafa nau'in ciwon sukari na 2: ƙira, haɓakawa, da wuri a cikin jiyya [J]. Drug Des Devel Ther, 2019,13:731-738.DOI:10.2147/DDDT.S165372.
[8] Hedrington MS, Davis S N. Oral semaglutide don maganin nau'in ciwon sukari na 2 [J]. Ra'ayin Kwararru Akan Pharmacotherapy, 2019,20(2):133-141.DOI:10.1080/14656566.2018.1552258.
Samfura akwai don amfani da bincike kawai:
